All the news Showing 10 of 51 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Cenicriviroc treatment improves liver fibrosis in people with NASH Liz Highleyman / 13 April 2018 Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatohepatitis (NASH) after two years of follow-up, according to a ... New EACS treatment guidelines Keith Alcorn / 31 October 2017 Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as people with hepatitis C monoinfection, ... Experimental therapy improves liver fat and fibrosis in people with NASH Liz Highleyman / 30 October 2017 GS-0976, an acetyl-CoA carboxylase (ACC) inhibitor being developed by Gilead Sciences, led to significant reductions in liver fat accumulation and fibrosis in people with non-alcoholic steatohepatitis (NASH), according to phase 2 study results ... Women with fatty liver disease at higher risk for heart disease Liz Highleyman / 24 October 2017 Women with non-alcoholic fatty liver disease (NAFLD) had a higher risk of cardiovascular events including chest pain and heart failure compared to women without the condition – and about the same risk as ... Cenicriviroc may reduce fibrosis in people with fatty liver disease Liz Highleyman / 05 October 2017 Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty ... Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors Michael Carter / 19 July 2017 Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results of a meta-analysis and systematic ... When you eat may contribute to fatty liver disease as much as what you eat Liz Highleyman / 17 November 2016 People who skip breakfast and eat late at night may have an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to research presented this week at the 2016 AASLD Liver Meeting in ... Coffee consumption linked to reduced liver fibrosis in people with HBV, HCV and NAFLD Liz Highleyman / 08 December 2015 Drinking coffee was associated with lower liver stiffness – a non-invasive measure used to estimate liver fibrosis – in people with hepatitis B, hepatitis C and non-alcoholic fatty liver disease (NAFLD), researchers reported ... Milk thistle may improve steatohepatitis, capsaicin from chilli peppers may slow fibrosis Liz Highleyman / 10 June 2015 People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomised, placebo-controlled trial, researchers reported at the European ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive